Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Yum! Brands, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while Yum! Brands, Inc. trades at $143 (market cap $39.02B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× Yum! Brands, Inc.'s market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Yum! Brands, Inc. for 132 Days on average.
| VRTX | YUM | |
|---|---|---|
Market Cap | $127.55B | $39.02B |
Volume | 1,487,944 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $168.16 |
52-Week Low | $407.37 | $135.77 |
Typical Hold Time | 120 Days | 132 Days |
Enterprise Value | $121.68B | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
YUM Brands trades at $140.35, up 0.36% today, with mixed technical signals showing bullish overall but bearish moving averages. The company demonstrates strong fundamentals with 2025 revenue of $8.21B and net income of $1.56B, though recent earnings show mixed quarterly performance. YUM completed the Pizza Hut sale for approximately $1.5B in September 2026, focusing on core brands KFC and Taco Bell.
YUM presents a compelling opportunity with analyst consensus target of $170.44 (21% upside), supported by consistent cash flow growth and strategic brand focus. Key risks include high debt levels ($11.25B long-term) and competitive pressures in the QSR space. The stock offers dividend stability with nine consecutive years of increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
